SYROS PHARMACEUTICALS INC COM USD0.001 (POST REV SPLIT) financial statements, including revenue, expenses, profit, and loss

The total revenue of 0LC7 for the last quarter is 386.00 k USD, and it's 89.74% lower compared to the previous quarter. The net income of Q4 23 is -64.38 M USD.